Dimethyl oxalate

We are Dimethyl oxalate CAS:553-90-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 553-90-2
Product Name: Dimethyl oxalate
Other Name:
Dimethyl oxalate
Dimethyl ethanedioate
Oxalicdimethylester
Oxalic acid dimethyl ester
 
Density: 1.2±0.1 g/cm3
Boiling Point: 163.5±0.0 °C at 760 mmHg
Melting Point: 50-54 °C(lit.)
Molecular Formula: C4H6O4
Molecular Weight: 118.088
Flash Point: 75.0±0.0 °C
Exact Mass: 118.026611
PSA: 52.60000
LogP: -0.34
Vapour Pressure: 2.1±0.3 mmHg at 25°C
Index of Refraction: 1.391
Stability: Stable. Combustible. Incompatible with strong oxidizing agents, acids, bases, reducing agents.
Water Solubility: 60 G/L (25 ºC)
 
Specification
Appearance: Colorless crystal
Assay: ≥99.0%
Water: ≤0.10%
 
Application
Mainly used in pharmaceutical, pesticide, organic synthesis, and also used as plasticizer.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Dimethyl oxalate


Related News: Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.4-(4-Bromophenyl)-6-phenyldibenzo[b,d]furan CAS:1556069-46-5 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.4-bromo-2-nitro-1-(trifluoromethyl)benzene INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.5-fluoro-2-yodotolueno CAS:28490-56-4 This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.

Related Products
Product Name
3,5-Bis(trifluoromethyl)benzaldehyde View Details
1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one View Details
2-Fluoro-4-iodobenzonitrile View Details
N4-acetylcytidine manufacturer 6-Bromo-5-chloropyridin-3-amine manufacturer ethyl (2Z)-2-chloro-2-[(4-methoxyphenyl)hydrazinylidene]acetate manufacturer 3-Fluoro-4-nitrobenzonitrile manufacturer 4,4-Difluoro-N-((1S)-3-oxo-1-phenylpropyl)cyclohexanecarboxamide manufacturer